The proportion of CD4+T cells of HCC patients was 31.45 ± 6.82, 39.87 ± 8.96, 39.64 ± 8.83% respectively prior to and 1–2 weeks and 3–5weeks after GSMs-TACE (P<0.01), CD8+T cells was 28.01 ± 7.56, 22.64 ± 5.59, 25.47 ± 7.70% respectively. The gene discussed is CD4; the disease is hepatocellular carcinoma.